APOB and coronary artery disorder: As expected, genetically mimicked ASGR1 inhibitors were associated with lower apoB, TG, apoA, total cholesterol, self-reported high cholesterol risk and CAD risk, and with higher HDL-cholesterol (Fig. 3).